HALO : Summary for Halozyme Therapeutics, Inc. - Yahoo Finance

U.S. Markets open in 7 hrs 43 mins

Halozyme Therapeutics, Inc. (HALO)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.04-0.03 (-0.25%)
At close: 4:00PM EST
People also watch
ZIOPFOLDCLDXACADACHN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close12.07
Open12.12
Bid9.12 x 200
Ask12.25 x 500
Day's Range11.72 - 12.30
52 Week Range7.52 - 14.38
Volume1,044,228
Avg. Volume1,829,229
Market Cap1.55B
Beta2.34
PE Ratio (TTM)-21.62
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire9 hours ago

    Halozyme Therapeutics To Present At Upcoming Healthcare Conferences

    SAN DIEGO, Feb. 23, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the Cowen & Company ...

  • PR Newswire11 days ago

    MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20

    SAN DIEGO, Feb. 13, 2017 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX), a clinical stage immuno-oncology drug development company, today announced results from a pre-clinical study evaluating the potential benefits of using MabVax's HuMab-5B1antibody, MVT-5873, currently in Phase I clinical trials for the treatment of metastatic pancreatic cancer with Halozyme Therapeutic's (HALO) investigational drug PEGPH20, which targets the tumor microenvironment potentially allowing increased access of co-administered cancer drug therapies to solid tumors.  PEGPH20 is currently in phase III clinical development for metastatic pancreatic cancer and in phase I clinical trials for non-small cell lung cancer, gastric cancer, and metastatic breast cancer. Results from the preclinical study were positive demonstrating improvement in accumulation of MVT-5873 on tumors in an animal model of pancreatic cancer when administered in sequence with PEGPH20.

  • Why Halozyme Therapeutics, Inc. Jumped 15.6% in January
    Motley Fool22 days ago

    Why Halozyme Therapeutics, Inc. Jumped 15.6% in January

    Shares rose in response to the release of upbeat clinical data from an important phase 2 study.